Analyst Group has published an updated analysis of Chordate Medical following the company’s Q2 report released on August 31, 2023. In the analysis, Analyst Group comments on Chordate’s sales efforts with a focus on a future exit strategy and the international attention garnered by the company’s migraine study:
“Chordate’s migraine study, PM007, was presented in June at the American Headache Society Scientific Meeting in Austin, Texas, as well as at the German Migraine and Headache Society congress in Berlin. The presentations were well-received and generated significant interest, with Chordate confirming the substantial need for an additional treatment option for chronic migraines through discussions with medical professionals. Subsequently, Chordate has been invited to present its migraine treatment at the International Headache Congress (IHC) 2023 in Seoul in September, and in October, Chordate will also be present at the Deutscher Schmerzkongress in Mannheim. In November, the company will participate in Neurologdagarna in Helsinki. It is abundantly clear that Chordate has rapidly gained and continues to receive a great deal of attention regarding its migraine treatment.”
